British Journal of Oral and Maxillofacial Surgery
Volume 47, Issue 8 , Pages 598-601, December 2009

A survey of consultant members of the British Association of Oral and Maxillofacial Surgeons regarding bisphosphonate-induced osteonecrosis of the jaws

  • S.N. Rogers

      Affiliations

    • Regional Maxillofacial Unit, University Hospital Aintree, Longmoor Lane, Liverpool L9 7LN, UK
    • Evidence-Based Practice Research Centre (EPRC), Faculty of Health, Edge Hill University, St Helens Road, Ormskirk L39 4QP, UK
    • Corresponding Author InformationCorresponding author at: Regional Maxillofacial Unit, University Hospital Aintree, Longmoor Lane, Liverpool L9 7LN, UK. Tel.: +44 0151 529 5287; fax: +44 0151 529 5288.
  • ,
  • J. Hung

      Affiliations

    • Regional Maxillofacial Unit, University Hospital Aintree, Longmoor Lane, Liverpool L9 7LN, UK
  • ,
  • A.J. Barber

      Affiliations

    • Regional Maxillofacial Unit, University Hospital Aintree, Longmoor Lane, Liverpool L9 7LN, UK
  • ,
  • D. Lowe

      Affiliations

    • Regional Maxillofacial Unit, University Hospital Aintree, Longmoor Lane, Liverpool L9 7LN, UK
    • Evidence-Based Practice Research Centre (EPRC), Faculty of Health, Edge Hill University, St Helens Road, Ormskirk L39 4QP, UK

Accepted 27 July 2009. published online 14 September 2009.

Abstract 

The aims of this survey of consultants in the British Association of Oral and Maxillofacial Surgeons were threefold. Firstly, to estimate the number of patients screened for oral health before starting intravenous bisphosphonate medication, secondly, to indicate the use of antibiotics in patients on bisphosphonates who need routine extraction of a lower first molar tooth, and finally to estimate the number of new and currently managed cases of bisphosphonate-induced osteonecrosis of the jaw (BONJ) in the last year, and approximately how many of those currently being managed had healed.

A questionnaire was mailed to 322 consultants working at 154 hospitals in the summer of 2008. There were responses from 184 consultants (57%) and from 111 hospitals (72%). Screening patients before starting intravenous bisphosphonates was uncommon (15%). Almost all consultants would prescribe antibiotics for molar extraction and in about two-thirds this was both before and after extraction. Relatively few would stop bisphosphonates. Nearly two-thirds of consultants had seen new cases of BONJ from intravenous treatment in the last year, and a quarter had seen three or more. A similar proportion had patients on intravenous bisphosphonates under review for BONJ, and it was estimated that in a fifth of patients the lesion had healed.

This survey indicates current practice among oral and maxillofacial surgeons in the UK. A national project for the registration of new patients will provide a stronger evidence base with respect to incidence, risk factors, and management of BONJ.

Keywords: Bisphosphonates, Bisphosphonate-induced osteonecrosis of the jaws, Survey, British Association of Oral and Maxillofacial Surgeons

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0266-4356(09)00483-5

doi:10.1016/j.bjoms.2009.07.020

British Journal of Oral and Maxillofacial Surgery
Volume 47, Issue 8 , Pages 598-601, December 2009